Ledger.Open graph →
SEC Form D · filed January 18, 2019

Summit Therapeutics plc

Offering
$25.0M
Sold
$25.0M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
ABINGDON, United Kingdom
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (14)

David Roblin · Abingdon, United KingdomExecGlyn Edwards · Abingdon, United KingdomExec · DirectorDavid Wurzer · Abingdon, United KingdomDirectorValeska Schroeder · MENLO PARK, CAExecStaffan Encrantz · MENLO PARK, CAExec · DirectorValerie Andrews · Abingdon, United KingdomDirectorLeopoldo Zambeletti · San Francisco, CADirectorFrank Armstrong · Abingdon, United KingdomDirectorFred H. Deserio · NEW YORK, NYExecSaurabh Bhansali · Chicago, ILExec · DirectorValerie Andrews · Abingdon, United KingdomDirectorDavid Wurzer · New Haven, CTDirectorLeopoldo Zambeletti · San Francisco, CADirectorFrank Armstrong · Abingdon, United KingdomDirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗